AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NYRADA INC-CDI

0.190

0.000

Volume:839.40K

Turnover:161.88K

Market Cap:40.07M

PE:-8.70

High:0.195

Open:0.190

Low:0.190

Close:0.190

Loading ...

Overview Company News Filings

Nyrada Receives Ethics Committee Approval to Modify Phase One Clinical Trial Protocol; Shares Fall 3%

MT Newswires Live

Nyrada Renames Lead Drug Candidate; Shares Down 4%

MT Newswires Live

Nyrada's Phase One Drug Trial Clears Safety Review

MT Newswires Live

Noxopharm Raises AU$2.5 Million Through Share Sale

MT Newswires Live

Nyrada Says NYR-BI03 Drug Candidate Shown to Provide Cardioprotection in Preclinical Cardiac Arrhythmia Study

MT Newswires Live

Nyrada Says Clinical Trial to Proceed to Third Cohort after Safety Review Committee Nod, Shares Rise 5%

MT Newswires Live

ASX Market Close: Investors wipe $97B in biggest rout since COVID | April 7, 2025

The Market Herald

Study finds Nyrada’s lead drug can prevent secondary brain injury

The Market Herald

ASX Small-Cap Stocks to Watch

MT Newswires Live

Nyrada Doses First Cohort in NYR-BI03's Phase I Human Clinical Trial

MT Newswires Live

ASX Midday Sector Update: Materials Stocks Soar, Healthcare Stocks Fall

MT Newswires Live

Nyrada Begins Patient Recruitment for NYR-BI03 Phase Ia Clinical Trial

MT Newswires Live

Nyrada Insiders May Regret Not Buying More, Market Cap Hits AU$18m

Simply Wall St.

BUZZ-Australia's Nyrada rises on nod to start brain injury drug's clinical trial

Nyrada Receives Ethics Approval for Phase 1a Trial; Shares Up 5%

MT Newswires Live

Pleasing Signs As A Number Of Insiders Buy Nyrada Stock

Simply Wall St.

Nyrada Submits Clinical Trial Regulatory Package for Ethics Committee Review

MT Newswires Live

Nyrada Inc-Nyr-Bi03 Phase Ia Clinical Trial Update 2

THOMSON REUTERS

Nyrada Inc-Nyr-Bi03 Phase Ia Clinical Trial Update - Correction

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NYR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NYR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","market":"AU","secType":"STK","nameCN":"NYRADA INC-CDI","latestPrice":0.19,"timestamp":1749190320000,"preClose":0.19,"halted":0,"volume":839396,"delay":0,"nameEN":"NYRADA INC-CDI","floatShares":126887816,"shares":210917037,"eps":-0.021836,"marketStatus":"Not Yet Opened","change":0,"latestTime":"06-06 16:12:00 AEST","open":0.19,"high":0.195,"low":0.19,"amount":161883,"amplitude":0.026316,"askPrice":0.19,"askSize":92445,"bidPrice":0.185,"bidSize":210675,"shortable":3,"etf":0,"ttmEps":-0.021836,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.19,"openAndCloseTimeList":[[1749168000000,1749189600000]],"volumeRatio":0.5511266635116628,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","floatShares":126887816,"roa":"-45.16%","roe":"-76.35%","lyrEps":-0.008535,"volumeRatio":0.5511266635116628,"shares":210917037,"dividePrice":0,"high":0.195,"amplitude":0.026316,"preClose":0.19,"low":0.19,"week52Low":0.032,"pbRate":"6.84","psRate":"24.30","week52High":0.195,"institutionHeld":0,"latestPrice":0.19,"committee":0.390044,"eps":-0.021836,"divideRate":0,"volume":839396,"delay":0,"ttmEps":-0.021836,"open":0.19,"prevYearClose":0.094,"prevWeekClose":0.19,"prevMonthClose":0.165,"prevQuarterClose":0.107,"fiveDayClose":0.165,"twentyDayClose":0.105,"sixtyDayClose":0.105},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NYR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540332670","title":"Nyrada Receives Ethics Committee Approval to Modify Phase One Clinical Trial Protocol; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540332670","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540332670?lang=en_us&edition=fundamental","pubTime":"2025-06-04 13:07","pubTimestamp":1749013678,"startTime":"0","endTime":"0","summary":"Nyrada  received human research ethics committee approval to modify its phase one clinical trial protocol, according to a Wednesday Australian bourse filing.The amendments allow for the evaluation of the safety, tolerability, and pharmacokinetics of Xolatryp, a small-molecule cardioprotection and neuroprotection therapy candidate, in healthy volunteers at higher doses and over a longer infusion duration.The phase one trial will consist of six cohorts, and results are expected in the September quarter.The amended protocol will give the firm greater flexibility in designing a phase two trial, including the ability to optimize dosing for the target patient population, per the filing.The firm's shares fell 3% in recent trading on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2537908600","title":"Nyrada Renames Lead Drug Candidate; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537908600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537908600?lang=en_us&edition=fundamental","pubTime":"2025-05-23 11:21","pubTimestamp":1747970481,"startTime":"0","endTime":"0","summary":"Nyrada  renamed its lead drug candidate targeting neuroprotection and cardioprotection to Xolatryp, according to a Friday filing with the Australian bourse.A trademark application for the name has been filed, the filing said.The drug candidate was previously referred to as NYR-BI03, according to the filing.Shares were down 4% in midday trade Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7096","XJO.AU","NYR.AU","XAO.AU"],"gpt_icon":0},{"id":"2537067987","title":"Nyrada's Phase One Drug Trial Clears Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2537067987","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537067987?lang=en_us&edition=fundamental","pubTime":"2025-05-21 10:53","pubTimestamp":1747795993,"startTime":"0","endTime":"0","summary":"Nyrada  said no issues were raised by the safety review committee after assessing phase one clinical trial data of its drug candidate NYR-BI03, developed to reduce brain and heart damage from brain injury and stroke, according to a Wednesday filing with the Australian bourse.The committee assessed cumulative safety and pharmacokinetic data from the first three cohorts of the trial, the filing said.Recruitment for the fourth cohort has been completed, the company added.Final results from the phase one trial are expected in the third quarter of the year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2536679676","title":"Noxopharm Raises AU$2.5 Million Through Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2536679676","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536679676?lang=en_us&edition=fundamental","pubTime":"2025-05-20 14:26","pubTimestamp":1747722400,"startTime":"0","endTime":"0","summary":"Noxopharm  said it has raised nearly AU$2.5 million in non-dilutive funding by selling its entire stake in Biotechnolgy company Nyrada , according to a Tuesday filing with the Australian bourse.The proceeds will be used to launch the upcoming Heracles clinical trial and invest in research and development, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7501","BK7096","NYR.AU","XJO.AU","XAO.AU","NOX.AU","BK7067","XKO.AU"],"gpt_icon":0},{"id":"2533239179","title":"Nyrada Says NYR-BI03 Drug Candidate Shown to Provide Cardioprotection in Preclinical Cardiac Arrhythmia Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2533239179","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533239179?lang=en_us&edition=fundamental","pubTime":"2025-05-08 14:12","pubTimestamp":1746684751,"startTime":"0","endTime":"0","summary":"Nyrada (ASX:NYR) said that a preclinical cardiac arrhythmia study showed that its NYR-BI03 small-molecule drug candidate provides strong cardioprotection when administered as a short-duration intraven","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2532852542","title":"Nyrada Says Clinical Trial to Proceed to Third Cohort after Safety Review Committee Nod, Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532852542","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532852542?lang=en_us&edition=fundamental","pubTime":"2025-05-02 10:34","pubTimestamp":1746153280,"startTime":"0","endTime":"0","summary":"Nyrada  said a phase one clinical trial safety review committee raised no issues after reviewing cumulative safety and pharmacokinetic data from the first and second cohorts in its clinical trial for the NYR-BI03 drug candidate, enabling the clinical trial to proceed to the third cohort, according to a Friday Australian bourse filing.NYR-BI03 is a small-molecule drug candidate for neuroprotection and cardioprotection indications.The trial is seeking to study the safety and tolerability of NYR-BI03 in healthy volunteers, as well as to determine the blood pharmacokinetics of an intravenous dose of NYR-BI03 when administered as a three-hour infusion.Its shares rose 5% in recent trading on Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"gpt_icon":0},{"id":"2525062724","title":"ASX Market Close: Investors wipe $97B in biggest rout since COVID | April 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525062724","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525062724?lang=en_us&edition=fundamental","pubTime":"2025-04-07 14:59","pubTimestamp":1744009140,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 4.2% at 7,343 points in a $97B wipeout for the market.The Energy sector was decimated, down 7%, followed by Financials, down 5%, and Materials and Discretionary – both down 4.8%.Lynas Rare News  closed up 3.1% after Aussie-listed miners of heavy rare earths rallied today, shrugging off major selloffs across other markets on bets Western governments would renew their push to develop a separate supply chain after top producer China set down export controls.Nyrada closed up 4.8% on reports of neuroprotective results for its lead drug candidate in a collaborative traumatic brain injury study with the Walter Reed Army Institute of Research and UNSW Sydney.Abacus Storage King  closed up 20.7% on news of an unsolicited takeover offer from a consortium, valuing the firm at around A$1.9 billion.Kelsian Groupfinished down 8.3% today despite developments in itsU.S.operations, where its wholly owned subsidiary, First Class Transportation, secured contract renewals and new bu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-investors-wipe-97b-in-biggest-rout-since-covid-april-7-2025-2025-04-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7161","BK7142","TLX.AU","BK7151","BK7507","WDS.AU","LYC.AU","BK7096","NYR.AU","KLS.AU","BK4211","ASK.AU","BK7067","BK7125","ISBC","BK7095"],"gpt_icon":0},{"id":"2525039449","title":"Study finds Nyrada’s lead drug can prevent secondary brain injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2525039449","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525039449?lang=en_us&edition=fundamental","pubTime":"2025-04-07 08:24","pubTimestamp":1743985440,"startTime":"0","endTime":"0","summary":"Nyrada Inc  has reported strong results from a collaborative study into traumatic brain injury at the University of Sydney, in which its lead drug candidate NYR-BI03 showed neuroprotective effectiveness.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.Nyrada is working with the Walter Reed Army Institute of Research and the University of New South Wales on the project, which revealed that NYR-BI03 could prevent secondary brain injury following a penetrating traumatic brain injury.Chair of the Scientific Advisory Board  and UNSW Scientia Professor Gary Housley said these results were significant. “This study provides strong evidence that Nyrada’s NYR-BI03 drug protected the brain following severe TBI.”Nyrada shares have been trading at 9.3 cents.Join the discussion:See what HotCopperusers are saying aboutNyrada Inc. and be part of the conversations that move the markets.The material p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/study-finds-nyradas-lead-drug-can-prevent-secondary-brain-injury-2025-04-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2525828086","title":"ASX Small-Cap Stocks to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2525828086","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525828086?lang=en_us&edition=fundamental","pubTime":"2025-04-07 07:45","pubTimestamp":1743983104,"startTime":"0","endTime":"0","summary":"Investors are likely to keep an eye on the following small-cap stocks listed on the Australian Securities Exchange.Nyrada (ASX:NYR)Nyrada's lead drug candidate, NYR-BI03, showed \"strong\" neuroprotecti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HNG.AU","BK7031","HCF.AU","BK7096","BK7509","GBE.AU","DES.AU","NYR.AU","BK7095","AKN.AU"],"gpt_icon":0},{"id":"2523501049","title":"Nyrada Doses First Cohort in NYR-BI03's Phase I Human Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2523501049","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523501049?lang=en_us&edition=fundamental","pubTime":"2025-03-31 13:17","pubTimestamp":1743398272,"startTime":"0","endTime":"0","summary":"Nyrada Inc.  has dosed and discharged the first cohort of its Phase I human clinical trial of its lead drug candidate, NYR-BI03, according to a Monday filing with the Australian bourse.The primary endpoint of the trial is to assess the safety and tolerability of NYR-BI03 in healthy volunteers, when administered as a three-hour intravenous infusion, per the filing.Six participants received NYR-BI03, while two others received a placebo. Readouts from the trial are expected in the third quarter.NYR-BI03 is a small molecule, first-in-class neuroprotection, and cardioprotection treatment.Nyrada's shares were down 2% on market close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2520553257","title":"ASX Midday Sector Update: Materials Stocks Soar, Healthcare Stocks Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2520553257","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520553257?lang=en_us&edition=fundamental","pubTime":"2025-03-17 10:34","pubTimestamp":1742178872,"startTime":"0","endTime":"0","summary":"Materials sector stocks advanced 1.73% at midday Monday, as iron ore prices moved higher. Meanwhile, stocks rallied on Wall Street on Friday after a US government shutdown was avoided.Ramelius Resources  and Spartan Resources  entered into a binding transaction implementation deed for Ramelius to acquire shares in Spartan that it does not already own in a deal that values Spartan at AU$2.4 billion.On the other hand, the healthcare sector fell 0.47%.Nyrada  began recruiting participants for the phase 1a clinical trial for the company's lead drug candidate, NYR-BI03, which is a small molecule, first-in-class neuroprotection, and cardioprotection treatment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4137","BK7104","BK4544","BK7096","HCSG","RMS.AU","ARKG","BK4585","BK4588","NYR.AU","SPAQ.U","SPR.AU","BK7506"],"gpt_icon":0},{"id":"2520532639","title":"Nyrada Begins Patient Recruitment for NYR-BI03 Phase Ia Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520532639","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520532639?lang=en_us&edition=fundamental","pubTime":"2025-03-17 09:43","pubTimestamp":1742175812,"startTime":"0","endTime":"0","summary":"Nyrada  has begun recruiting participants for the phase Ia clinical trial for the company's lead drug candidate, NYR-BI03, according to a Monday filing with the Australian bourse.NYR-BI03 is a small molecule, first-in-class neuroprotection, and cardioprotection treatment. The trial will be a double-blind, randomized, placebo-controlled, dose-escalating study, comprising five cohorts of eight participants, the filing stated.First participant dosing is expected before the end of March, while final phase Ia trial readouts are likely in the third quarter of the year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2510079199","title":"Nyrada Insiders May Regret Not Buying More, Market Cap Hits AU$18m","url":"https://stock-news.laohu8.com/highlight/detail?id=2510079199","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510079199?lang=en_us&edition=fundamental","pubTime":"2025-02-10 08:20","pubTimestamp":1739146838,"startTime":"0","endTime":"0","summary":"Nyrada Inc.  insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 15% resulting in a AU$2.3m addition to the company’s market value. In other words, the original AU$210.0k purchase is now worth AU$238.0k.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.The Non-Executive Chairman John Moore made the biggest insider purchase in the last 12 months. That single transaction was for AU$100k worth of shares at a price of AU$0.075 each. We do like to see buying, but this purchase was made at well below the current price of AU$0.085. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We curre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nyrada-insiders-may-regret-not-002038290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2509275453","title":"BUZZ-Australia's Nyrada rises on nod to start brain injury drug's clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2509275453","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509275453?lang=en_us&edition=fundamental","pubTime":"2025-02-07 11:42","pubTimestamp":1738899746,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Nyrada rises on nod to start brain injury drug's clinical trial** Nyrada NYR.AX soars 9.2% to A$0.083, highest since Jan. 23; set for biggest intraday pct gain since Dec. 16, 2024** B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nL4N3OY0A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7096","NYR.AU","BK7067","NOX.AU","BK7508"],"gpt_icon":0},{"id":"2509755724","title":"Nyrada Receives Ethics Approval for Phase 1a Trial; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509755724","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509755724?lang=en_us&edition=fundamental","pubTime":"2025-02-07 10:37","pubTimestamp":1738895872,"startTime":"0","endTime":"0","summary":"Nyrada  received approval from the Human Research Ethics Committee to start its first-in-human phase 1a clinical trial evaluating the safety, tolerability, and pharmacokinetics of drug candidate NYR-BI03, according to a Friday filing with the Australian bourse.NYR-BI03 is a treatment that has the potential to protect both brain and heart tissue.The double-blind, randomized, placebo-controlled study will administer either NYR-BI03 or placebo to five groups of eight healthy volunteers, with six active and two placebo participants per group, the filing said.The first dosing is expected to begin by the end of March, according to the filing.Nyrada's shares were up 5% in afternoon trade Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NYR.AU"],"gpt_icon":0},{"id":"2505208554","title":"Pleasing Signs As A Number Of Insiders Buy Nyrada Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2505208554","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505208554?lang=en_us&edition=fundamental","pubTime":"2025-01-23 04:44","pubTimestamp":1737578648,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nyr/nyrada-shares/news/pleasing-signs-as-a-number-of-insiders-buy-nyrada-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2495668007","title":"Nyrada Submits Clinical Trial Regulatory Package for Ethics Committee Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2495668007","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495668007?lang=en_us&edition=fundamental","pubTime":"2024-12-31 10:36","pubTimestamp":1735612612,"startTime":"0","endTime":"0","summary":"Nyrada  submitted its phase IA first-in-healthy human volunteer clinical trial regulatory package of drug candidate NYR-BI03 for Human Research Ethics Committee review, according to a Tuesday filing with the Australian bourse.The biotechnology company is developing NYR-BI03 for the potential treatment of stroke and traumatic brain injury, the filing said.The review, scheduled for January 2025, will allow for the start of volunteer recruitment for the trial, according to the filing.Shares rose past 2% in afternoon trade Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2495506862","title":"Nyrada Inc-Nyr-Bi03 Phase Ia Clinical Trial Update 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2495506862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495506862?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:46","pubTimestamp":1735595194,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nTUE7DYX0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NYR.AU","BK7096"],"gpt_icon":0},{"id":"2492640171","title":"Nyrada Inc-Nyr-Bi03 Phase Ia Clinical Trial Update - Correction","url":"https://stock-news.laohu8.com/highlight/detail?id=2492640171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492640171?lang=en_us&edition=fundamental","pubTime":"2024-12-17 05:14","pubTimestamp":1734383660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUE2BYYFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NYR.AU\",params:#limit:5,,,undefined,":[{"date":"2023-07-28","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690502400000,"name":null,"time":"","dateTimestamp":1690466400000,"actualEps":null},{"date":"2023-04-29","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1682726400000,"name":null,"time":"","dateTimestamp":1682690400000,"actualEps":null},{"market":"AU","date":"2022-08-29","symbol":"NYR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661695200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NYR.AU\",market:\"AU\",,,undefined,":[]}}